Eden Bioscience Corp Q4 2016 Institutional Investor Sentiment Worse Than Expected

June 19, 2017 - By Adrian Erickson

 Eden Bioscience Corp  Q4 2016 Institutional Investor Sentiment  Worse Than Expected

Sentiment for Eden Bioscience Corp (LON:EDEN)

Eden Bioscience Corp (LON:EDEN) institutional sentiment increased to 0.85 in Q4 2016. Its up 0.62, from 0.23 in 2016Q3. The ratio increased, as 11 funds started new or increased stock positions, while 13 reduced and sold positions in Eden Bioscience Corp. The funds in our partner’s database now hold: 412,649 shares, up from 296,168 shares in 2016Q3. Also, the number of funds holding Eden Bioscience Corp in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 7 Reduced: 6 Increased: 5 New Position: 6.

Eden Research plc is a technology development and commercialization company. The company has market cap of 18.23 million GBP. The Firm focuses on plant protection, animal and human health, and biocides. It currently has negative earnings. The Company’s divisions include Biocides, Human health and Agrochemicals.

About shares traded. Eden Research plc (LON:EDEN) has 0.00% since June 19, 2016 and is . It has underperformed by 16.70% the S&P500.

Amg National Trust Bank holds 0.23% of its portfolio in Eden Research plc for 55,559 shares. Zacks Investment Management owns 22,173 shares or 0.03% of their US portfolio. Moreover, Flow Traders U.S. Llc has 0.02% invested in the company for 5,599 shares. The New York-based Jane Street Group Llc has invested 0.02% in the stock. Sg Americas Securities Llc, a New York-based fund reported 46,317 shares.#img1#

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.